Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases

Clinical trial NCT05003986 · RECRUITING

Trial details

NCT number: NCT05003986
Sponsor: Travere Therapeutics, Inc.
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Focal Segmental Glomerulosclerosis Minimal Change Disease Immunoglobulin A Nephropathy IgA Vasculitis Alport Syndrome

Start date: 2021-08-12
Primary completion: 2027-03-12
Enrollment: 67

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.